Influenza Hemagglutinin And Neuraminidase Variants

a technology of hemagglutinin and neuraminidase, which is applied in the field of influenza hemagglutinin and neuraminidase variants, can solve the problems of immuno-compromised persons, elderly, and those without adequate health care, and achieve the effects of reducing the risk of death from such infections

Inactive Publication Date: 2008-03-20
MEDIMMUNE LLC +1
View PDF36 Cites 78 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0166] Expressed polypeptides of the invention can contain one or more modified amino acids. The presence of modified amino acids can be advantageous in, for example, (a) increasing polypeptide serum half-life, (b) reducing / increasing polypeptide antigenicity, (c) increasing polypeptide storage stability, etc. Amino acid(s) are modified, for example, co-translationally or post-translationally during recombinant production (e.g., N-linked glycosylation at N-X-S / T motifs during expression in mammalian cells) or modified by synthetic means (e.g., via PEGylation).

Problems solved by technology

Infants, the elderly, those without adequate health care and immuno-compromised persons are at special risk of death from such infections.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Influenza Hemagglutinin And Neuraminidase Variants
  • Influenza Hemagglutinin And Neuraminidase Variants
  • Influenza Hemagglutinin And Neuraminidase Variants

Examples

Experimental program
Comparison scheme
Effect test

example 1

Construction and Analysis of H5N1 ca Viruses and Vaccines

[0221] Various sequences herein comprising H5N1 HA / NA sequences were used to create influenza viruses and vaccines. The HA sequences in such vaccines were altered from wild-type by removal of the polybasic cleavage site within the HA. The HA / NA sequences were reasserted (in a 6:2 reassortment) with ca A / AA / 6 / 60 (a ts, att, ca virus, see above).

[0222] Three strains of H5N1 influenza were used in this example: A / VN / 1203 / 2004, A / HK / 491 / 1997, and A / HK / 213 / 2003. Such strains are also referred to within this example as the '97, '03, and '04 strains based on their year designations. The HA sequence homology of these three strains is 95-96%. FIG. 1 illustrates modification of the polybasic cleavage site of an exemplary HA sequence, the '04 HA sequences, used to construct the viruses / vaccines. As stated previously, various embodiments of the invention comprise sequences which have differing regions of the polybasic cleavage site remo...

example 2

Construction and Analysis of H6 ca Viruses and Vaccines

[0233] A set of three recombinant influenza viruses and vaccines comprising H6 HA sequences were prepared: (a) A / Duck, which comprised the H6 HA and N9 NA of A / Duck77; (b) A / Teal, which comprised the H6 HA and N1 NA of A / Teal97; and (c) A / Mallard, which comprised the H6 HA and N2 NA of A / Mallard85. The six internal genome segments of each recombinant virus were those of ca A / AA / 6 / 60.

[0234] Each of the A / Duck, A / Teal, and A / Mallard recombinant viruses was attenuated in nasal turbinates and lungs of ferrets. Ferrets were intranasally inoculated with 107 TCID50 recombinant (ca; see paragraph immediately above) or wild-type (wt) H6 influenza virus. Nasal turbinate and lung tissue was harvested from the ferrets three days post-infection for examination. FIG. 16 shows that the nasal turbinate and lung tissue of ferrets inoculated with recombinant virus (ca) exhibited lower virus titers than did the nasal turbinate and lung tissue of...

example 3

Construction and Analysis of an H7N3 BC 04 ca, Virus and Vaccine

[0238] A further recombinant influenza virus and vaccine was prepared using the HA H7 and NA N3 sequences of A / ck / BC / CN-6 / 04 (BC 04 ca). These HA and NA sequences were combined with the six internal genome segments of ca A / AA / 6 / 60.

[0239] The BC 04 ca vaccine was attenuated in the ferrets. Ferrets were intranasally inoculated with 107 TCID50 vaccine in 0.5 mL. Three days following inoculation, ferret nasal turbinates, lungs, brain, and olfactory bulb were harvested. Virus titer in each of these tissues was diminished in ferrets inoculated with the vaccine virus relative to ferrets inoculated with wt viruses A / BC / CN-6 / 04 or A / BC / CN-7 / 04. See FIG. 19.

[0240] The BC 04 ca vaccine was immunogenic in mice. In mice receiving the BC 04 ca vaccine, neutralizing antibodies were detected at 4 weeks and these titers rose over 8 weeks. A second dose of vaccine boosted antibody titer but final titer achieved was similar to that fol...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperature sensitiveaaaaaaaaaa
humidityaaaaaaaaaa
Login to view more

Abstract

Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit under 35 U.S.C. § 119 (e) of U.S. Provisional Application Nos. 60 / 821,832 filed Aug. 9, 2006 and 60 / 942,804, filed Jun. 8, 2007, the disclosures of each of which are incorporated herein in their entirety for all purposes.BACKGROUND OF THE INVENTION [0002] Vaccines against various and evolving strains of influenza are important from a community health stand point, as well as commercially, since each year numerous individuals are infected with different strains and types of influenza virus. Infants, the elderly, those without adequate health care and immuno-compromised persons are at special risk of death from such infections. Compounding the problem of influenza infections is that novel influenza strains evolve readily and can spread amongst various species, thereby necessitating the continuous production of new vaccines. [0003] Numerous vaccines capable of producing a protective immune response specif...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/145A61K35/76A61K39/00A61P31/16C12N1/19C12N15/63C12N7/01C12P21/00C12N5/10C12N1/21C07K14/00A61K39/395A61K39/12
CPCA61K39/00A61K39/145A61K2039/5252A61K2039/5254A61K2039/543C12N7/00C12N2760/16122C12N2760/16134C12N2760/16164C07K14/005A61K39/12A61P31/16A61P37/04A61P43/00
Inventor YANG, CHIN-FENKEMBLE, GEORGESUBBARAO, KANTAMURPHY, BRIAN
Owner MEDIMMUNE LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap